We provide an overview of recent developments in big data analyses in the context of precision medicine and health informatics. With the advance in technologies capturing molecular and medical data, we entered the area of Big Data in biology and medicine. These data offer many opportunities to advance precision medicine. We outline key challenges in precision medicine and present recent advances in data integration-based methods to uncover personalized information from big data produced by various omics studies. We survey recent integrative methods for disease subtyping, bio-markers discovery and drug repurposing, and list the tools that are available to domain scientists. Given the ever-growing nature of these big data, we highlight key issues that big data integration methods will face.
Introduction
Precision medicine, also known as personalized, predictive, preventive and participatory (P4) medicine 1 , is an emerging approach for individualizing the practice of medicine 2 . Prevention and treatment strategies that take into account individual variability are not new; for example, blood-typing has been used to guide blood transfusion for more than a century, with a total of 35 human blood groups being recognized by the International Society of Blood Transfusion. 3 Similarly, gender, race, time of ischaemia, cytomegalovirus and sero-type are taken into account to reduce the risk of rejecting organ transplantations [4] [5] [6] [7] . The challenge in applying the precision medicine concept to omics and clinical data sets of patient features that have become available and that cannot be interpreted directly by medical practitioners due to their large sizes and complexities.
Big data is a broad term for data sets so large or complex that traditional data processing methods are inadequate. It is often characterized by three Vs 8 : volume, which refers to the large size of the data, velocity, which refers to the high speed at which data are generated, and variety, which refers to the heterogeneity of the data coming from different sources. All these characteristics apply to currently available biological and medical datasets. Since the beginning of the Human Genome Project 9 , novel technological developments led to the era of omics sciences. Using novel high-throughput capturing technologies, we are now able to access the DNA of an individual (genetic data), the transcribed RNA over time (expression and co-expression data), proteins (protein profiles and protein interaction data), metabolism (metabolic profiles) and epigenome (DNA methylation data), among other data types 10 . The environment is also taken into account (e.g., nutrition and bacterial environment by nutriomics and metagenomics, respectively) 11, 12 , and also histopathological and medical imaging data are now subject to high throughput capturing and analysis methods [13] [14] [15] [16] . Therefore, we are facing an increasing gap between our ability to generate big biomedical data and our ability to analyse and interpret them 17 . In this context, it is not surprising that big data and precision medicine are jointly investigated. In 2011, the "Big Data Research and Development Initiative" 1 was targeting personalized medicine through the GenISIS program (Genomic Information System for Integrated Science) to enhance health care for Veterans. In 2012, the US National Institutes of Health (NIH) launched the "Big Data to Knowledge" initiative, to harvest the wealth of information contained in biomedical Big Data 18 . Finally, President Obama recently announced the "Precision Medicine" initiative 2 , with an ambitious goal of driving precision medicine by incorporating many different types of data, from genomes to microbiomes, with patient data collected by health care providers and patients themselves.
Out of many challenges in precision medicine, here we focus on four related problems: patient sub-typing, bio-marker discovery, drug repurposing and personalized treatment prediction. We provide a review of methods capable of integrative analyses of multiple data types in addressing these problems. have been shown to be likely regulated via the same mechanisms 39 and differential expression patterns are used to identify dysregulated genes in cancer 40 , predict possible drug-targets 41 and cancer outcomes 42 .
as human microbiome consists of circa 100 trillion microbial cells, which is about ten times the number of human cells 59 .
Biomedical data gets more complex
The complexity of biomedical data grows in two directions: in terms of the number of samples and in terms of heterogeneity.
The growing number of samples. As capturing technologies are becoming faster and cheaper, the number of individuals for whom data is available is quickly increasing. For example, the number of available human genomes/exomes increased almost exponentially during the last decade: the first human exome was released in 2003 9 , while in 2012, 1,092 human genomes were available 60 . Nowadays, the Exome Aggregation Consortium contains 60,706 unrelated human exomes. 4 The United Kingdom government recently announced the project to map 100,000 human genomes by 2017 5 and the precision medicine initiative in the US plans to map 1 million human genomes. Note that this increasing number of genome samples will also come at the price of increasing variations in terms of genome quality. Next generation sequencers produce short reads that need to be assembled into genomes. The quality of the assembled genome highly depends on the ratio between the sum of the short read lengths and of the target genomic sequence length. This ratio is called the depth of the sequencing and it is expressed in terms of X (e.g., 2X sequencing means that on average each nucleotide is covered by two short reads). While current sequencing uses ≈ 30X, a recent study argues that high quality genomes may require ≈ 126X (refereed as deep sequencing) 61 .
Moreover, for the same individual, an increasing number of samples is captured; data can be collected over different tissues, by using single cell genomics 62 , or on different conditions (e.g., before and after treatment). Finally, the time span of available samples is increasing. For example, gene expression can be measured over time to assess the effect of drugs. Recent developments of non-intrusive capturing techniques (e.g., fetal exome sequencing from maternal blood 63 and magneticresonance-imaging (MRI), capturing brain connectivity maps from unborn babies to adults 6 ) will allow collecting information over the whole life span of an individual, which paves the way to personalized medicine from womb to tomb.
Increasing heterogeneity of captured data. The number of different biological entities (e.g., genes, RNAs, proteins, metabolites, drugs, diseases, etc.) for which data can be collected is increasing. The variety of available data is illustrated in Table 1 , which presents some of the well established large scale biomedical databases. The collected data are so large that even basic data management is becoming challenging. US healthcare was already storing 150 exabytes (10 18 Bytes) of data in 2011 and is expected to handle yottabytes of data (10 24 Bytes) in the next few years 7 .
These datasets are highly heterogeneous; data from the same type can be captured with different technologies having varying coverage, bias and noise robustness (e.g., the different technologies for capturing protein-protein interactions 64 ), and the same applies across data types. Moreover, the large number of data sources poses data collection issues coming from the lack of standard format in data repositories (so-called data-extraction problem in Big Data 65 ).
Machine learning techniques
As described in the previous section, Big Data are of large-scale, diversity and complexity, and as such they require efficient algorithms for extracting knowledge hidden in them. Computational techniques that are used to analyse Big Data are either based on statistical, machine learning (ML), or network-based (NB) methods 104 . These methods have already demonstrated great potential in bridging the gap between production and interpretation of big data in precision medicine, but there is still a lot of room for their improvements.
ML methods came into focus of Big Data analysis due to their prominent ability to collectively mine (integrate) large-scale, diverse and heterogeneous biomedical data types, a foremost challenge in precision medicine and medical informatics 105 . Thus, in this section, we mostly focus on ML methods for data integration, but we also mention some recent statistical and NB methods for data integration.
ML methods can be divided into the following classes (see Fig. 2 for an illustration):
• supervised methods, such as classification and regression, take as input training data samples with known labels. A model is learned through a training process that maximises the accuracy of its performance on the training data set. The model is then used for mapping new data samples to existing labels. For example, an input data can comprise patients classified as cases and controls. A model is learned to maximise the difference between cases and controls and then it is applied in classification of new patients. Some of the widely used supervised techniques include Support Vector Machines (SVM) 106 , Kernel-based methods 107 and Logistic regression 108 . 99 www.t3db.org ∼ 3,600 common toxins and environmental pollutants FooDB 100 www.foodb.ca ∼ 28,000 food components/additives, with presumptive health effects UMCD 101 umcd.humanconnectomeproject.org 1,887 brain connectivity matrices from neuroimaging data HCP 102 www.humanconnectome.org/data MRI captured brain connectivity maps of 500 adult individuals HMP 103 hmpdacc.org 11,000 samples of human microbiomes from 300 adult individuals Table 1 . Available data for human. The databases presented in the first row contain genomic data. The databases presented in the second row contain epigenomic data. The databases presented in the third row contain transcriptomic data. The databases presented in the fourth row conatain proteomic data. The databases presented in the fifth row contain metabolomic and glycomic data. The databases presented in the sixth row contain phenomic, exposomic and metagenomic data.
• unsupervised methods, such as clustering and dimensionality reduction, take as input unlabelled data set. A model is learned by revealing hidden patterns in the data and organising the data into meaningful subsets. These methods are often used in molecular subtyping of cancer patients, or in discovering of patterns in gene expression data. Some of the widely used unsupervised methods in precision medicine include hierarchical clustering 109 , K-means 109 and its generalisations including matrix factorization methods 110 .
• semi-supervised methods take as input a mixture of labelled and unlabelled samples. A model is learned to explain the structure in the data as well as to make new predictions of unlabelled samples. For example, in predicting new drug-disease associations, semi-supervised methods learn known drug-disease associations from labelled samples (i.e., prior knowledge), to predict novel drug-disease associations. This strategy is particularly suitable for data integration, as is can incorporate various data types as prior knowledge. One of the most widely used such method is network-regularised matrix factorization 111 .
Based on the type of data they integrate, the integration methods can be divided into homogeneous, where the same type of data, but across multiple perspectives (e.g., experimental studies) is integrated, and heterogeneous, where multiple data types in different formats are integrated. The later is computationally more challenging, because it requires a framework that can deal with heterogeneous data without transforming it and losing any information through the transformation. A majority of the existing frameworks cannot cope with this issue and they require a pre-processing step prior to integration, where they transform the data into a single representation. In Section 3.2, we discuss this issue in more detail and identify methods capable of addressing this problem.
We survey recent integrative methods for disease sub-typing, biomarker discovery and drug repurposing, and provide a summary listing computational tools that can be used by domain scientists for analysing of Big Data (see Table 2 for the list of methods). The presented methods are chosen based on the following criteria: (1) the method is integrative (i.e., it considers more than one data type) and is applied on biomedical Big Data; (2) the method is predominantly based on Machine Learning (ML) techniques, although we also consider couple of network-based methods; and (3) the method has been used to address one of the the four different precision medicine challenges (see Section 1).
Computational methods for disease sub-typing and bio-marker discovery
Disease sub-typing (or disease stratification) is a task of grouping patients into subgroups based on genomic, transcriptomic, epigenomic and clinical data. The main goal of sub-typing is achieving more accurate prognoses of individuals' expected outcomes that can be used to improve treatment decisions. Treatments of many diseases have benefited from sub-typing, including Parkinson's, cardiovascular, autoimmune diseases and cancer 112 .
Cancer is one of the most studied diseases by sub-typing. It is a disease in which genome aberrations are accumulating and eventually leading to dysregulation of the cellular system. Histologically similar cancers are composed of many molecular subtypes with significantly different clinical behaviours and molecular complexity at the genomic, epigenomic, transcriptomic and proteomic levels. Many sub-types have been identified by utilising techniques for data integration for various cancer types, including colon and rectal 113 , breast 114 and ovarian cancer 115 .
Unsupervised clustering ML methods, such as hierarchical clustering 116 , k-means 117 , consensus clustering 118 and nonnegative matrix factorization 119 have mostly been applied to gene expression data, by comparing expression levels of disease genes across different samples to identify meaningful subgroups. The most recent of such methods propose to divide patients into clinically relevant subtypes by comparing differentially expressed genes (based on normal and cancer tissue samples) 116 . Based on the selected set of differentially expressed genes, they calculate the distance between patients and perform hierarchical clustering 109 . Using mRNA expression data of breast and lung cancer patients, they identified four breast cancer and five lung cancer subtypes with significantly different survival rates. Moreover, instead of identifying individual driver mutations, they identify driver mutation modules for each individual subtype. Namely, by using the protein-protein interaction (PPI) network and by mapping the top 15 most frequently mutated genes of each identified subtype onto the network, they search for an optimally connected sub-network covering these genes. The identified sub-networks are postulated as driver modules that can serve as new targets for repurposing of known drugs and their combinations 116 . Many other studies have also focused on developing methods for identifying aberrant network modules and pathways by utilizing molecular networks and other omics data. For example, Alcaraz et al. 120 developed KeyPathwayMiner, a method for extraction of aberrant network modules from PPI network by integrating gene expression and DNA methylation data. The authors demonstrated the performance of KeyPathwayMiner on TCGA colorectal cancer patients. The method uses heuristic techniques based on ant colony optimization
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to extract maximally connected sub-networks with a certain number of differentially expressed genes in all patients. The resulting sub-networks was shown to be enriched in genes with over active signalling in colorectal cancer that can be interpreted as potential therapeutic targets. Similarly, Vaske et al. 121 developed PARADIGM, a method for inferring patient-specific altered molecular pathways. The methods also allows for identification of common altered pathways among different patients and thus providing patient sub-typing. The authors applied PARADIGM on TCGA gene expression and DNA copy number variations data of glioblastoma multiform patients; based on the significant pathway perturbations the authors divide patient into four different subgroups with significantly different survival outcome.
However, a majority of recent methods use integrative approaches to combine multiple types of molecular data, such as DNA copy number alteration, DNA methylation, mRNA and protein expression, and molecular interaction data, accounting for different levels of variations among affected individuals and thereby providing more accurate sub-typing 122, 123 . For example, Shen et al. 124 developed iCluster, an unsupervised learning framework that can simultaneously perform clustering, data integration, feature selection and dimension reduction of multiple data types. It uses a probabilistic matrix factorization approach to simultaneously decompose data matrices, representing different data types (e.g., DNA methylation, DNA copy number variations, mRNA expression data) over the same number of samples (patients), into a common feature space represented by two low-dimensional matrices (Fig. 3(A) ). Specifically, they decompose the data matrices by simultaneously factorizing each data matrix into a product of two low-dimensional matrices. The dimensionality of the low-dimensional matrices represents the number of cancer subtypes and it is a predefined parameter. The first matrix, also called the coefficient matrix, is specific to each data type, while the second matrix, also called the cluster indicator matrix, is shared across the decomposition. The second matrix captures the dependencies across the data types, and based on its entries it is used for a single, integrated assignment of tumor samples to clusters (subtypes). The authors applied iCluster on DNA copy number variation and gene expression data to stratify breast and lung cancer patients. After obtaining the probabilistic representation of the low-dimensional, cluster indicator matrix, they assign tumor samples to different subgroups. In both the breast and lung cancer data examples, they identify novel subgroups with statistically different clinical outcomes as a result of combined information from the both data types 124 .
(A) (B) Figure 3 . Illustration of MF-based methods. (A) Matrix factorization of multiple data matrices, X i , representing different data types (e.g., mRNA expression, DNA methylation, copy number variation, etc.) over the same number of samples p. The matrices are decomposed into a common feature space, represented by matrix Z, that is also a cluster indicator matrix; it is used for assigning p samples into k clusters. Matrices W i called coefficient matrices are specific to each data set i. (B) Tri-factorization of the data matrix R representing relations between two data sets of sizes n 1 and n 2 (e.g., drug-target interactions) into three low-dimensional matrices. Matrices G 1 and G 2 are cluster indicator matrices for the first and second dataset respectively; matrix G 1 (G 2 ) is used for assigning n 1 (n 2 ) data points to k 1 (k 2 ) clusters. Matrix S is the low-dimensional representation of R.
iCluster is a widely used tool and it has been applied for subtyping of various cancers. For example, Curtis at al. 125 , applied it to breast cancer patients from METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort and identified ten subgroups with significantly different outcomes. Moreover, they reported significant correlation between genome variations and gene expression data and based on that, they discovered novel putative genes for breast cancer 125 . iCluster was also applied on TCGA glioblastoma multiforme (the most common and most aggressive malignant brain tumor) data set by simultaneous clustering of DNA copy number variation, methylation and gene expression data 126 . The authors reveal three distinct tumor subtypes of glioblastoma multiforme, as opposed to the four distinct subtypes reported by previous studies that used solely gene expression data 22 . This demonstrates the power of integrative analysis over analyses of single data types in characterising, classifying and predicting clinical outcomes of cancer patients.
The first method that deals with detection of contradictory signals across different data types is proposed by Yuan et al. 127 . They propose a Patient Specific Data Fusion (PSDF) method based on non-parametric Bayesian approach to integrate gene expression and copy number variation data of prostate and breast cancer patients 127 . A Bayesian approach is a statistical
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ML approach that builds a model of data by constructing conditional dependencies between data variables represented by conditional probabilities. One of the widely used methods for learning conditional probabilities is Markov chain Monte Carlo (MCMC) technique 128 . Unlike other methods, this method successfully detects contradictory signals between different data types arising from different measurement errors. Specifically, a latent variable is assigned to each patient; it measures whether or not the patient's data are concordant (i.e., in agreement) across different data types. This approach allows for contradictory data information to be suppressed in the patient clustering assignment. The biggest drawback of this approach is that it does not scale well with the number of data types and thus, the authors restrict their analysis only on two data types. Namely, the MCMC step is computationally the most intensive and requires around 48 hours for a single MCMC chain to complete. Despite this drawback, the authors report a novel subtype of prostate cancer patients with extremely poor survival outcome 127 .
To further take into account data inconsistency across data types, iCluster was further generalised by Ray et al. 129 by introducing Bayesian joint factor model built upon iCluster framework. Namely, instead of having a single cluster indicator matrix common for all data types, they further decompose it into shared and data-specific matrix components. Specifically, the cluster indicator matrix is represented as a sum of data type specific and common low-dimensional feature matrices. The common and specific low-dimensional matrices are learned jointly via simultaneous decomposition of all data matrices. This generalisation was shown to be particularly useful for joint analysis of multi-platform genomic data, as it allows more flexibility in the decomposition of distinct data types. Moreover, the authors reported better performance of their model compared to iCluster, because unlike iCluster, that enforces all tumor samples to be included into the clustering procedure, the proposed model can selectively choose between more and less correlated samples across data types when performing clustering assignment. The authors demonstrated their method on TCGA gene expression, copy number variation and methylation data of ovarian cancer patients, particularly for uncovering key driver genes in ovarian cancer 129 . Similarly, Lock et al. 130 introduced JIVE (Joint and Individual Variation Explained), a method which instead of having the same coefficient matrices for shared and data-specific components proposed a model with different coefficient matrices corresponding to joint and data-specific components capturing low-dimensional joint variations across data types, as well as variations specific to each data type. With this extension, JIVE performed a better characterisation of tumor subtypes, as well as a better understanding of the biological interactions between different data types 130 .
To overcome scalability drawbacks of the previous ML clustering methods, that operate with high-dimensional gene × patient matrices, Wang et al. 131 proposed a network-based method that integrates data represented by patient × patient matrices. This method, called Similarity Network Fusion (SNF), combines mRNA expression, DNA methylation and microRNA expression data for the same set of cancer patients. First, for each data type, it constructs a weighted network of patients, with nodes being patients and weighted links being similarities between patients. The similarities are computed based on their gene profiles for a particular data type. Second, it normalises weights of each network by taking into account the networks from all data types. Finally, it fuses all the networks into a single network by performing a diffusion of information within each network and across different networks. After the convergence of the diffusion process, the authors use a spectral clustering method 132 on the final fused network to group patients into clusters. Unlike the previous methods, SNF is more scalable. Namely, instead of processing large-scale matrices constructed over a large number of genes, SNF method fuses much smaller matrices representing networks constructed over patients (i.e., samples), which makes the convergence faster. SNF is shown to be robust to noise and when applied on five different cancer types from TCGA database, it was shown to be effective in prediction of patient survival outcomes 131 .
A majority of studies are based on analysing mRNA expression data from RNA sequencing and microarrays, and DNA copy number alteration data. Because of noisiness of these data, the patient stratification studies for cancer types often do not produce patient subgroups that agree well with any clinical, or survival data 113 . To overcome these shortcomings, Hofree et al 133 recently proposed the use of somatic mutation data as a new source of information for cancer patient stratification. However, highly heterogeneous somatic mutation profiles between different patients make the use of somatic mutations for patient stratification into subtypes much harder 115, 133, 134 . Namely, two clinically identical tumors rarely have a large set of common mutated genes. Moreover, very few genes are frequently mutated across tumor samples. However, despite this genetic diversity between tumor samples, the perturbed pathways are often similar 134 . Therefore, Hofree et al. 133 proposed to address this problem by integrating somatic mutations with molecular networks that contain pathways. Their method, called Network-based Stratification (NBS), is based on network-regularised non-negative matrix factorization 135 . Namely, they factorize patient-gene binary matrix, encoding patients' somatic mutation profiles, into a product of two low-dimensional, non-negative matrices; the second of which being the cluster indicator matrix. The non-negativity constraint provides an easier interpretation of clustering assignment of tumor samples. They further incorporate molecular networks into the clustering procedure by constraining the construction of the cluster indicator matrix to respect the local network connectivity. This semi-supervised approach uses molecular networks as prior knowledge about clusters, ensuring that the patients are grouped not only based on the similarity of their somatic mutation profiles, but also based on the proximity of their mutated genes in the molecular network. Using the consensus clustering method 118 applied on the final cluster indicator matrix, the authors stratify patients into different
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subgroups. The method was applied on ovarian, uterine and lung cancer patients from TCGA database, and it yielded cancer subtypes with different clinical outcomes, response to therapies and tumor histologies.
MF-based methods are promising for mining heterogeneous datasets. These methods have a potential to incorporate any number and type of heterogeneous data and to perform comprehensive analyses. We recently made a step towards this goal and extended the NBS method to incorporate drug data into the framework 136 . Unlike the previous, our method is more comprehensive because it can simultaneously perform three tasks: cancer patient subtyping, drug repurposing and biomarker discovery (driver gene identification). We used Graph-regularized Non-negative Matrix Tri-Factorization (GNMTF) 111 (see Fig. 3(B) for an illustration) approach to integrate somatic mutation profiles of ovarian cancer patients, molecular networks, drug-target interactions and drug chemical similarity data. We simultaneously tri-factorize patient-gene and drug-target matrix by sharing common low-dimensional matrix factors representing cluster indicator matrices. We compute three different cluster indicator matrices used for clustering assignment of genes, patients and drugs, respectively. The computation of the gene cluster indicator matrix is constrained by connectivity of integrated molecular network, whereas the computation of the drug cluster indicator matrix is constrained by drug chemical similarities. The integrated network is composed of three different molecular networks, namely, PPI, genetic and metabolic interaction networks. Given that GNMTF is both a co-clustering and dimensionality reduction approach, we use GNMTF to perform the following three tasks; 1) we use the patient cluster indicator matrix to stratify ovarian cancer patients into different subgroups with different clinical outcomes; 2) we use the gene cluster indicator matrix to uncover gene modules enriched in driver mutations and postulate new genes as drivers of tumor progression; and 3) we use the matrix completion property of the drug-target matrix to predict novel drug-target interactions and discover new drug candidates that can be repurposed to treat ovarian cancer patients.
Challenges and open questions. Identification of disease subtypes has been shown to be both data and method dependent. Moreover, there is no consensus in the literature about the number of subtypes of a particular cancer type. Depending on the methods and data types they use, different studies report different numbers of subtypes of a particular cancer type (e.g., breast cancer). Also, unsupervised methods require the number of subtypes to be predetermined. Determining the number of subtypes is not a straightforward task and different approaches can be used to discover the correct number of clusters in the data. For example, iCluster uses a cross-validation technique 124 , while NBS determines the number of subtypes based on the stability of the consensus clustering 133 . Furthermore, there is an urgent need for a reference data set that should be used in future studies for systematic evaluation and comparisons of methods.
Moreover, many of the above mentioned integrative methods for subtyping are incapable of simultaneously considering different data types. For example, SNF method can only integrate data types given by continuous variables (e.g., mRNA expression levels), as they can be easily used for construction of similarity networks. However, SNF cannot incorporate somatic mutation profiles, as it cannot construct a similarity network from highly heterogeneous somatic mutation profiles. Namely, due to the small overlap between somatic mutation profiles across different patients, it is difficult to define a proper similarity measure between patients. Approaches such as NBS and GNMTF are more convenient for integration of somatic mutation profiles. Very few studies integrate somatic mutation data with mRNA and methylation data, due to the difficulty in integrating binary with continuous data types 137 .
A proper normalisation of different data types is another issue in integrative data analyses. If not properly accounted for it often results in cases where the largest data set wins. Unlike iCluster, JIVE properly takes into account the data normalisation problem 130 .
Computational methods for drug repurposing and personalised treatments
Various computational methods for drug repurposing have been proposed and they can be classified under different criteria. For example, from the data viewpoint, Dudley et al. 148 suggested classification into drug-based and disease-based methods. The first group of methods uses some notion of similarity between drugs (e.g., chemical similarity 149 , similarity between gene expressions induced by drug actions 74 , or drug-side effect similarity 150 ) to group drugs and infer a novel drug candidate for repurposing from the group that can perform the same action as other drugs in the group. The second group of methods uses similarities between diseases (e.g., phenotype similarity 151 , or similarity between disease symptoms 152 ) to group diseases and to infer a novel drug for repurposing by expanding known associations between the drug and some members of the group to the rest of the group. Other approaches use target-based similarities 153 , i.e., protein sequence similarity 154 , or 3D structural similarity 155 , to infer novel drugs. On the other hand, all three approaches can be classified as similarity-based approaches 153 . They often use either machine-learning, or network-based methods in the drug inference process. Other computational approaches include molecular docking simulation approaches that deal with prediction of a binding place of a drug within protein 3D structure 156 . However, the biggest limitations of these methods are the lack of knowledge of 3D structures for many protein targets and extensive computational costs for testing a single drug-target interaction.
A full review of similarity-based and molecular docking approaches for single data type analyses is beyond the scope of this article and we refer the reader to recent review articles by Li et al. 157 and Ding et al. 153 . Here, we focus on integrative
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Method name
Description
Underlying method Learning strategy PSDF 127 Patient stratification by integrating DNA copy number variation and mRNA expression data.
Bayesian model unsupervised
KeyPathwayMiner 120 Identification of aberrant sub-networks by integrating PPI network with gene expression and DNA methylation data.
Network-based semi-supervised PARADIGM 121 Inference of patient-specific pathways and patient stratification by integrating DNA copy number variations and mRNA expression data.
Network-based unsupervised iCluster 124 Cancer patient stratification by integrating copy number variation and mRNA expression data.
Matrix factorization unsupervised
Joint Bayesian factor 129 Driver genes identification by integrating mRNA expression and methylation data.
Matrix Factorization unsupervised
JIVE 130 Cancer patient stratification by integrating mRNA expression and miRNA expression data.
Matrix factorization unsupervised
SNF 131 Patient subtyping by integrating patient similarity networks constructed from mRNA expression, DNA methylation and miRNA expression data.
Network-based unsupervised NBS 133 Cancer patient stratification by integrating somatic mutation data with molecular networks.
Matrix factorization semi-supervised GNMTF 136 Patient stratification, drug repurposing and identifications of driver mutations by integrating of somatic mutations, molecular networks, drug-target interactions and drug chemical similarity data.
Matrix factorization semi-supervised
Joint kernel matrices 138 Drug repurposing by integrating of drug chemical structures, PPI network and drug induced gene expression data.
Kernel-based supervised
PreDR 139 Drug repurposing and prediction of novel drug-disease associations by integrating drug chemical structures, drug side-effects and protein target structures.
MSCMF 140 Drug-target interaction prediction by integrating known drug-target interactions along with multiple drug and target similarities.
Matrix factorization semi-supervised DDR 141 Drug-disease association prediction by integrating known drug-disease association along with multiple drug and target similarities.
Matrix factorization simi-supervised PREDICT 142 Inference of novel drug indications by integrating multiple drug and target similarities.
Logistic regression supervised
Coupled network propagation 143 Drug-disease network inference by integrating drug, disease and gene interaction network, as well as drug-gene and gene-disease association network
Network-based unsupervised
Network completion 144 Drug repurposing by integrating drug-target, drug-disease and disease-target networks.
SMirN 145 Inference of drug-miRAN network by integrating cancer related miRNA target gene expression and transcriptional responses to drug compounds.
Kolmogorov-Smirnov unsupervised
HGLDA 146 Inference lncRNA-disease network by integrating miRNA-disease associations and lncRNA-miRNA interactions.
Hyper geometric test unsupervised
Regularised NMF 147 Disease causing lncRNA prioritisation by integrating lncRNA-disease associations, along with lncRNA and coding gene expression data and lncRNA-coding gene association data.
Matrix factorization semi-supervised Table 2 . Summary of methods for integrative analyses in precision medicine. The first group of methods is used for sub-typing and biomarker discovery; the second group is used for drug repurposing and therapy prediction. Some methods can be belong to both categories (e.g., GNMTF).
methods capable of integrating various similarities from different data types containing complementary information, such as pharmacological, chemical, genetic and clinical data. Namely, due to heterogeneity and complexity of many diseases characterised with different subtypes, drugs are not always equally efficient in treatment of the same disease. Thus, the overarching goal of precision medicine is to take into account molecular diversity between individuals when diagnosing patients and prescribing drugs specific to each individual 158 . With the Big Data initiative (see Section 2), integrative computational approaches have started attracting more attention due to their ability to address this goal. For example, Napolitano et al. 138 used a kernel-based (KB) method 106 to integrate drug chemical similarity, PPI network and drug induced gene expression data after a patient treatment. Each data is represented by a kernel matrix in a drug-centered feature space. Particularly, the three kernel matrices represent drug-drug similarities based on: 1) drug chemical structures from DrugBank; 2) proximity of their targets in the PPI network; and 3) correlations between gene profiles under the drug's influence retrieved from CMap database. After combining these kernel matrices into a single kernel matrix, the authors applied a Support Vector Machine (SVM), a supervised machine learning method for classification. They trained the SVM on the existing drug classification achieving 78% of classification accuracy and they used the top scoring misclassified drugs as new candidates for repurposing 138 . A similar approach was used by Wang et al. 139 , who developed a PreDR (Predict Drug Repurposing) method where drug-centered kernel matrices represent: 1) drug chemical similarities obtained from PubChem database; 2) target (protein) sequence similarities retrieved from KEGG BRITE and DrugBank; and 3) drug side-effect similarities for SIDER database. The disease-centered kernel matrix represents disease similarities measured by their semantic similarity of disease phenotypes retrieved from OMIM database. The authors trained the SVM classifier on the combined kernel matrix and reported accuracy in identifying novel drug-disease interactions.
Zheng et al. 140 developed an integrative framework called Multiple Similarities Collaborative Matrix Factorization (MSCMF) for drug-target prediction. It takes as an input a matrix representing drug-target interactions, as well as multiple matrices representing different types of similarities between drugs and targets constructed from various databases. MSCMF projects drugs and targets into a common low-dimensional feature space by factorizing the drug-target matrix into a product of two low-dimensional matrices representing drug and target low-dimensional feature vectors, respectively. The computation of low-dimensional matrices of drugs and targets is done in a semi-supervised manner by constraining their values to be consistent with drug-drug and target-target similarity matrices, respectively. Namely, the similarity between two drugs is approximated by the inner product of their corresponding feature vectors. The same is applied on target feature vectors. The authors mathematically formulated the factorization condition and constraints within the same objective function, which they minimise by applying the Alternating Least Squares (ALS) algorithm 159 . After convergence, they reconstructed the drug-target matrix from the obtained low-dimensional matrices (i.e., from matrix completion) and extracted new, previously unobserved entries representing predicted drug-target interactions. MSCMF is shown to perform better than the previous state-of-the-art methods for drug-target prediction. Moreover, the big advantage of MSCMF over the previous methods is the fact that it can integrate similarities from multiple data sources over the same set of drugs or targets and estimate their influence onto the quality of the drug-target prediction.
Similar to MSCMF, Zhang et al. 141 proposed DDR (Drug Disease Repositioning), a semi-supervised, matrix tri-factorizationbased framework for novel drug-disease association prediction. It takes as input known drug-disease associations, as well as multiple drug and multiple disease similarity networks and generates new drug-disease associations. In particular, it constructs three drug similarity matrices based on their chemical structures, side-effects and target proteins and three disease similarity matrices based on their phenotypes, Disease Ontology and disease genes. The predicted associations are validated in clinical trial databases. Unlike MSCMF, DDR factorizes drug-disease associations into a product of three low-dimensional matrices, where the first and the last matrices can be interpreted as cluster assignment matrices of drugs and diseases, respectively. These matrices can be used to identify subgroups of highly correlated drugs and diseases, thus providing additional insights for drug repurposing by identifying a group of similar drug candidates that can be used in clinical trials.
Gottlieb et al. 142 developed a supervised method, called PREDICT (PREdicting Drug IndiCaTions). First, it computes drug-drug and disease-disease similarity measures from five and six different drug and disease data sources, respectively. Second, based on these similarities, it constructs an overall similarity for each drug-disease pair. Finally, based on the drug-disease similarity, it trains a logistic regression classifier on correctly classifying known drug-disease associations. The authors demonstrated a great accuracy of PREDICT in identifying novel indications of drugs with Area Under the ROC curve (AUC) 160 of 0.92. Moreover, they propose PREDICT as a general framework that can be used in future personalized drug treatments by incorporating gene expression data of disease patients into the framework.
All previous methods use either supervised, or semi-supervised strategy in predicting drug-target, or drug-disease associations and thus, they require a gold standard (i.e., a set of known associations) to train their models. For many specific diseases, that data set is unknown, or incomplete, which makes the use of the methods more difficult. To overcome this, Huang et al. 143 proposed a completely unsupervised integrative method that can infer drug-disease associations without any prior associations. They used coupled network propagation 161 on drug-drug chemical similarity, disease-disease phenotype similarity and gene-gene co-expression similarity homogeneous networks, connected by drug-gene and gene-disease heterogeneous networks. They applied their method on data for prostate and colorectal cancer patients. They identified top scoring drugs predicted to be used in treatment of these groups of patients. Another unsupervised, network-based method for heterogeneous network integration and drug repurposing was introduced by Daminelli et al. 144 . They predicted novel drug-target associations by completing incomplete bi-cliques in the integrated drug-target-disease network. They demonstrate the power of their method by predicting novel drugs for cardiovascular and parasitic diseases, as well as by predicting novel drugs for cancer-related kinases. For other network-based methods for drug repurposing we refer a reader to a recent review paper by Wu et al. 162 .
Non-coding RNAs, in particular microRNAs (or miRNAs) and long non-coding RNAs (lncRNAs), have recently started attracting attention due to their involvement in various diseases, including cancer and autoimmune disorders 163 and thus, have been proposed as potential biomarkers 146, 164 and drug targets 165, 166 . Due to large collections of transcriptional and drug data being available, new computational methods for identification of miRNAs as potential drug targets have recently been proposed. For example, Jiang et al. 145 proposed a framework for construction of a network, SMirN, of interactions between small drug molecules (compounds) and miRNAs using data from different human cancers. Specifically, they used transcriptional responses to compounds and differentially expressed miRNA target genes in 23 different human cancers. For each miRNA, they partitioned their target genes into GO modules, and for each GO module they evaluated the association between its differentially expressed target genes and the transcriptional response to the compound by using Kolmogorov-Smirnov test. If these associations are confirmed for a significant number of GO modules of a particular miRNA, then the authors hypothesized a link between the miRNA and the corresponding drug compound. They analysed the SMirN network and separately grouped miRNAs and compounds into modules, based on which they infer novel potential miRNA targets, as well as novel drug compounds that can be used in drug repurposing for cancer therapy. Chen 167 developed a novel model of HyperGeometric distribution for lncRNA-Disease Associations (HGLDA) inference. The model integrates known miRNA-disease associations and lncRNA-miRNA interactions and without a gold standard data set, it infers a network of lncRNA-disease associations with AUC of 0.76 in the leave-one-out cross validation. Based on the top 19 predicted associations, they reported novel lncRNAs involved in breast, lung and colorectal cancer that can be used as novel biomarkers for diagnosis of these cancers. A more sophisticated integrative method, based on non-negative matrix factorizaton, was recently proposed by Biswas et al., 147 . They factorize lncRNA-disease association matrix into a product of two non-negative, low-dimensional matrices specific to lncRNAs and diseases, respectively. The non-negativity of the obtained, low-dimensional matrices allows for easier extraction of lncRNA and disease subgroups in the data. They can also be interpreted as cluster assignment matrices for lncRNAs and diseases, respectively. The factorization of the lncRNA-disease association matrix was done in a semi-supervised way, by constraining the construction of the low-dimensional matrices with additional data, including coding gene and lncRNA expression data, as well as lncRNA-coding gene association network. The authors identified several biologically relevant lncRNA and disease groups. Based on the membership scores in the lncRNA low-dimensional matrix, they ranked disease causing lncRNAs for each particular disease. They identified a prominent group of lncRNAs associated with heart diseases, as well as a group of lncRNAs strongly associated with neurological disorders that can be used in future experimental testing as biomarkers of these disorders.
Challenges and open questions. Many of the methods presented in this section require different data types to be represented in common feature space. For example, KB methods (e.g., PreDR) require the matrices of all data types to be constructed over the same set of entities (e.g., drugs, or diseases). This often requires transforming the data that may lead to information loss. On the other hand, MF-based methods (e.g., MSCMF) can handle these heterogeneous data without any data transformation and thus, without any information loss. Also, many methods require choosing an appropriate similarity measure to integrate various data types. This is not always a straightforward task and different measures may results in different final conclusions. Similar to the methods described in section 3.1, the methods for drug-target (and drug-disease) prediction and drug repurposing are lacking a reference corpus of data for comparing their performances.
Challenges and perspectives
As presented in Section 2, biomedical data are increasingly becoming available and dealing with their "three V" components will impose many challenges and open questions. For example, in addressing Big Data's volume (i.e., high dimensionality), many dimensionality reduction techniques have been devised, reviewed in Sections 3.1 and 3.2. However, they are all computationally intensive on large-scale data sets and devising techniques that are both efficient and accurate in revealing hidden substructures in them is still an open question. One of the possible solutions to addressing this question might be Topological Data Analysis methods (TDAs) 168, 169 . TDAs use mathematical concepts developed in algebraic topology. TDAs analyse Big Data by converting them into low-dimensional geometric representations from which they extract shapes (patterns) and obtain insight into them. These methods have been shown to be more efficient in finding substructures in large-scale data sets than standard methods, such as clustering, or principal component analysis methods. Moreover, they succeed in finding hidden structures in the data that standard methods failed to discover 169 .
Dealing with Big Data's velocity (i.e., coping with its growth over time) is particularly challenging and poorly addressed in the literature on precision medicine. One of the possible future directions in addressing this challenge is the utilisation of so-called "anytime algorithms" 170 that can learn from streaming data (e.g., time-dependent Bayesian classifiers) 171 and that still return a valuable result if their execution is interrupted at any time. Moreover, in the future, we will have access to more and more time series data. At the moment, such times series are either pre-processed to find patterns, e.g., time series of expression data are either used to find genes with time-correlated expression (co-expression network), or used to study the effect of drugs on short time scales by differential expression analysis. With the increasing number of measured features and the increasing time span of the measurements, a key challenge will be to find a data integration model that will directly mine time series measurements for which the time spans and frequencies of measurements vary greatly.
The Big Data's variety (i.e., heterogeneity) has been addressed by many methods as presented in Section 3.2. MF-based methods are promising for mining heterogeneous datasets. Although GNMTF is a versatile data integration framework 136 , its computational complexity increases with the number of data types to be integrated. Thus, integrating large numbers of heterogeneous data types within the MF-based framework necessitates novel algorithmic improvements.
Extracting complementary information conveyed in data of different formats and types is another challenge that is partially addressed by the presented integrative methods. For example, proteomics data have been shown to be a good complement to other omics data. Namely, many studies have confirmed that proteins having physical interactions in a PPI network are more
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likely to have correlated co-expression profiles of their corresponding genes 172 . On the contrary, protein physical interactions are less likely to coincide to genetic interactions (GI) of the their corresponding genes 173 . Thus, integrating GI network with PPI network and other molecular networks has been shown to be beneficial in many biological problems 133, 136, 174 .
Moreover, many data types including exposomics and metagenomics data are yet to be analysied and their integration with other data will be a focus of future studies. For example, much of an individual's health data, such as demographic data, personal and family medical history, vaccination records, laboratory tests and imaging results are systematically being collected and stored in Electronic Health Records (EHR). EHR data are increasingly becoming available for academic research purposes and they present numerous computational challenges that are yet to be addressed. Two major computational challenges include developing algorithms for: 1) individual phenotyping (i.e., annotating patient records with disease conditions) 175 and 2) integration of EHR data with omics data for better understanding of disease mechanisms and treatments 176 . The biggest obstacles of the first challenge are nosiness and incompleteness of the EHR data that needs to be properly taken into account. On the other hand, the biggest obstacles of the second challenge are heterogeneity and different format types of EHR and genomic data. Some steps towards addressing these challenges have been made 175, 176 , but developing methods that can overcome these obstacles are yet to come.
Finally, while we focus on the four challenges of precision medicine, big data integration also opens novel opportunities in bioinformatics and in other data sciences. For example, it can be used to reprocess raw data in more coherent way, or with novel research questions in mind 177 .
